# GPT-5-mini Review

**Role:** External referee review
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-01T10:06:24.719142
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 16263 in / 7208 out
**Response SHA256:** a8caa4ecd6854df9

---

Thank you for the opportunity to review this paper. I evaluate both format and content carefully and give detailed, actionable feedback. My overall judgment is that the paper addresses an interesting and policy-relevant question (the housing-market effects of the Dutch nitrogen ruling) and uses a plausible method (synthetic control). However, the current manuscript has multiple important limitations in methodology, identification, robustness, and exposition that must be addressed before it can be considered for a top general-interest journal. I therefore recommend MAJOR REVISION. Below I give a structured, rigorous review with specific required fixes, missing literature the authors must cite, tests and analyses they must add, and advice about writing and presentation.

1. FORMAT CHECK (required fixes)
- Length:
  - The provided LaTeX source includes a full paper plus substantial appendices and figures. Counting the body (Title → Conclusion) and appended sections, the file appears to produce on the order of a few dozen pages. However, the main manuscript (Title through Conclusion, excluding appendices and references) appears to be substantially shorter than the 25-page guideline for a top general-interest submission. My read of the document structure suggests the main text (Introduction → Conclusion) is roughly 15–20 pages of printed text (hard to be exact from source), with appendices adding many pages. For AER/QJE/JPE standards the main text (not including extensive appendix) should be expanded with more substantive material (especially more granular empirical analysis and robustness). Please report explicitly (in the cover letter) the page count of the main text excluding references and appendices and bring the core paper to ~25+ pages of substantive narrative (unless the journal asked otherwise).
  - Action: Explicitly state in the manuscript header how many pages the main body has (excluding references/appendix). Expand the main text with more substantive robustness and heterogeneity (see suggestions below).
- References / Bibliography:
  - Strength: The bibliography cites core synthetic control references (Abadie et al. 2003, 2010, 2015) and some environmental/housing literatures. Good start.
  - Shortcoming: Several key methodological and applied papers relevant to inference for synthetic control, alternative estimators (augmented SCM, matrix completion), and DiD/stacked-event literature are missing (see Section 4 below with required citations and BibTeX).
  - Action: Add and engage with the methodological literature listed below; add more recent applied work on housing regulation and environmental policy trade-offs where relevant (see Section 4).
- Prose / Major sections:
  - The major sections (Introduction, Institutional Background, Conceptual Framework, Data, Empirical Strategy, Results, Discussion, Conclusion) are written in standard paragraph form. That is satisfactory.
  - However, several subsections (e.g., the empirical strategy and robustness checks) use bullet lists in places (Data subsubsections and the description of robustness checks). That is acceptable in methods but the Introduction, Results and Discussion are in paragraph form (OK). No major failure here.
- Section depth:
  - Several major sections are short or under-developed relative to top-journal expectations. For example:
    - The Introduction is a single long section but could be richer: it summarizes findings well but lacks a sharper statement of the paper’s unique contribution relative to the literature and clearer preview of empirical challenges. The Intro appears to be ~1.5–2 pages and qualifies for expansion.
    - The Discussion (Section 7) has only a few substantive paragraphs; the policy implications and limitations section need deeper development (including alternative mechanisms and explicit policy takeaways).
  - Action: Expand each major section so each contains at least three substantive paragraphs laying out context, methods, results, and limitations in a cohesive narrative.
- Figures:
  - Figures appear to show data and are referenced in text. However:
    - In the LaTeX source, figures are included as PNGs (e.g., figures/fig1_synth_control.png). Ensure all figures in final production are vector (PDF/SVG) with legible fonts and lines at print size.
    - Every figure must have clearly labeled axes (units, index base), legend, data source, and sample period in the caption. Some captions already do this but standardize formatting and move long notes into a footnote-like Figure Note. For example, indicate explicitly "Real HPI, 2010Q1=100" on the y-axis label and ensure the x-axis tick labels are legible quarterly dates.
  - Action: Replace raster images with vector graphics, ensure fonts and sizes are publication-quality, and add fuller explanatory notes for each figure.
- Tables:
  - The tables contain real numbers and summary statistics; no placeholders observed. Good.
  - Improvements needed: report sample sizes (N) in all regression and aggregate tables (see Statistical Methodology below); attach standard errors/confidence intervals appropriately.
  - Action: For every table with estimates, include standard errors in parentheses, 95% CIs, number of observations, number of pre/post periods, and any test statistics used.

2. STATISTICAL METHODOLOGY (critical — must be addressed)
A paper cannot pass review without proper statistical inference. The manuscript uses a synthetic control method and reports some inference via placebo tests; nevertheless there are several critical methodological concerns. I list them and indicate whether the current implementation passes or fails the corresponding requirement.

a) Standard errors:
- The manuscript reports an ATT = 4.52 and a “Std. Error = 1.06” in Table 6 (Panel B). The text explains that this SE is computed as SD(gaps)/sqrt(n) where n = 19 post-treatment quarters and explicitly admits this measures time-series variability of the gap rather than sampling uncertainty from a finite population.
- Assessment: This is not an appropriate standard error for causal inference in synthetic control settings. Synthetic control inference is not achieved by that time-series SE; rather, inference should come from permutation/placebo distributions (Abadie et al. 2010) or from recent advances in conformal inference/augmented SCM/JASA approaches. The paper reports placebo p-values (p = 0.69) but also continues to present the parametric SE/CI without sufficient justification. This is misleading.
- Result: FAIL as-is on rigorous SEs. The paper must report robust inference based on accepted SCM practices and be transparent about what is being tested.

b) Significance testing:
- The paper implements in-space placebos (Section 6.5 and Table 9) and reports a placebo p-value (0.69). This is the standard non-parametric SCM inference approach and is appropriate in principle.
- However, the execution can be improved in several ways (see constructive suggestions). At present the placebo p-value provides no evidence of an effect — this should be emphasized, not downplayed.
- Requirement: Show placebo distributions graphically (sorted post/pre RMSE ratios), compute p-values based on RMSPE ratios as recommended by Abadie (2010), and also test alternative nulls (e.g., effect magnitude thresholds) if of interest.

c) Confidence intervals:
- The manuscript reports a 95% CI for ATT built from the time-series SE (ATT ± 1.96*SE). Because that SE is not appropriate, the CI is not valid for causal inference.
- Action required: Remove the parametric CI or clearly state it is descriptive and not inferential. Provide inference via permutation p-values and, if possible, present uncertainty bands from recent inferential methods for SCM (see suggested literature below: Conformal inference for SCM; augmented SCM inference).

d) Sample sizes:
- The paper reports T0 and n (pre/post quarters) in many places (good). For all regression-like estimates (if any are added) and any tabulated comparisons, report the relevant N. Table notes should explicitly state the number of treated units (1), donor units (J=15), pre-treatment periods (T0=37), and post-treatment periods (n=19). For any DiD or cross-country regression used for comparison, show sample sizes and cluster adjustments.
- Action: Ensure every table with estimates shows sample sizes and degrees of freedom explicitly.

e) DiD with staggered adoption:
- Not applicable directly because the analysis is a national-level synthetic control with a single treatment date (no staggered adoption). The paper includes a “DiD Comparison (Reference Only)” in Table 6 (Panel D) but does not rely on it.
- However, it would be helpful to explain why DiD is not appropriate here (single treated unit; national shock; country-level confounders) and to reference the literature on problems with TWFE and staggered timing (Goodman-Bacon, Callaway & Sant’Anna) if the authors use any DiD variants in extensions. If authors introduce any panel regressions later, they must heed that literature.
- Action: If any DiD analyses are used to complement SCM, use modern two-way-fixed-effects-aware estimators (e.g., Callaway & Sant’Anna, Sun & Abraham) or justify why simple DiD is acceptable.

f) RDD:
- Not applicable. No RDD attempted.

Summary of methodology verdict:
- The synthetic control approach itself is reasonable for a single nationwide shock, but the manuscript fails to present valid statistical inference as currently reported (parametric SE/CI are inappropriate), and the placebo analysis, while present, is not conducted/presented with the depth required for a top journal and shows the effect is not statistically distinguishable from noise. Unless the authors can strengthen the identification and inference substantially, the empirical conclusion is not credible.
- Therefore: As currently implemented the methodology is insufficient for publication in a top journal. This is a fatal flaw unless corrected. State clearly: the paper is not publishable in current form.

3. IDENTIFICATION STRATEGY (credibility, assumptions, robustness)
3.1 Credibility
- Identification attempts to exploit the sharp timing of a national legal ruling (May 29, 2019) and constructs a synthetic Netherlands from other European countries. The logic is straightforward.
- Strengths: The ruling is indeed discrete in time and nationwide, which is a typical candidate for SCM. The authors demonstrate excellent pre-treatment fit (R^2 = 0.95; RMSE = 1.77). They also sensibly check leave-one-out and pre-COVID windows.
- Weaknesses (critical):
  - Confounding by COVID-19. The ruling occurred only a few months before the global pandemic. The paper rightly flags that the bulk of the estimated divergence appears during 2020–2022 and that the pre-COVID effect (2019Q2–2019Q4) is tiny (0.58). This substantially undermines a causal attribution to the nitrogen ruling at the national level.
  - Donor-weight concentration. The synthetic control places 42%/38%/21% weight on Portugal/Spain/France alone. That extreme concentration implies the counterfactual heavily depends on the post-2019 dynamics of a few Southern European countries that have structural differences with the Netherlands (mortgage markets, demographics, housing cycles). The leave-one-out results confirm huge sensitivity: excluding Spain reverses the sign; excluding Portugal multiplies the ATT. This is a major identification weakness.
  - Heterogeneous treatment exposure. The nitrogen ruling most directly affected areas near Natura 2000 sites and the Randstad. National-level HPI averages could dilute local effects and make attribution problematic.
  - Mechanism not directly tested. There are no direct supply-side variables (building permits, starts, completions) in the analysis, so the paper relies on the theory that permits declined and supply tightened. The paper references construction permit decline anecdotal estimates but lacks systemic evidence.
  - Placebo tests do not support rejecting the null. The reported placebo p-value is 0.69. The authors nonetheless present ATT point estimates as if they had causal import. That is inconsistent.
3.2 Key assumptions discussion
- The SCM relies on the assumption that a convex combination of donor country outcomes can approximate Netherlands’ pre-trend and, absent treatment, would continue to reflect the counterfactual. The paper discusses this implicitly but should make the assumption explicit (what confounders are allowed to vary, what unobservables are being approximated by donors).
- The authors must show diagnostic checks beyond pre-RMSE: e.g., show the distribution of pre-treatment RMSPE across donors, report the ratio of post/pre RMSPE, and show the time-series of placebo gaps. Also report the extent to which the Netherlands lies in the convex hull of donor pre-treatment trajectories (leave-one-out weight stability is a start).
3.3 Placebo/robustness checks adequacy
- Placebo tests performed but:
  - The analysis should present a figure of the distribution of post-treatment ATT or post/pre RMSPE ratios across placebos, with the Netherlands highlighted (standard SCM presentation).
  - The authors include donors with poor pre-fit in the p-value calculation (the table notes that some donors have very large pre-RMSE). Abadie et al. recommend discarding donors with poor pre-treatment fit (e.g., whose pre-RMSE exceeds some multiple of treated pre-RMSE) when computing permutation p-values. The paper should present p-values both with and without poorly fitting donors and report the RMSPE ratio tests.
  - The manuscript should implement the Augmented Synthetic Control (Ben-Michael et al.) or synthetic difference-in-differences (Arkhangelsky et al.) and compare results. Given large weight concentration and post-2019 common shocks, Augmented SCM can reduce bias from poor fit and extrapolation.
3.4 Do conclusions follow from evidence?
- Not yet. Given:
  - The large concentration of donor weights and sensitivity to donor composition,
  - The negligible immediate (pre-COVID) effect,
  - The lack of supportive placebo p-values,
  high confidence in the causal claim that the nitrogen ruling raised national house prices by 5% is not justified. The correct conclusion at this stage is that the evidence is suggestive at best and heavily confounded by pandemic-era dynamics. The manuscript already acknowledges this to some extent, but the abstract and intro still present the 5% estimate prominently; that presentation should be tempered.
3.5 Limitations discussion
- The Discussion lists many of the right limitations (single treated unit, COVID confounding, national-level aggregation, no direct supply measures). The authors should expand and incorporate these points earlier in the paper and particularly in the abstract / intro where claims are strongest. Also discuss sampling uncertainty from synthetic-control inference, not just time-series variability.

4. LITERATURE (required additions and BibTeX)
The literature review needs to engage more fully with (a) modern inference and extensions for synthetic control, (b) alternative estimators addressing similar problems, and (c) the TuD/DiD literature if the authors ever compare to panel regressions. At minimum, cite and discuss the following methodological papers and explain how your inference or methods relate:

- Abadie, Diamond, Hainmueller (already cited) — good. Keep.
- The Augmented Synthetic Control Method: Ben-Michael, A., Feller, A., & Rothstein, J. (2021). This is essential: it provides an estimator that improves finite-sample properties and addresses extrapolation bias which is particularly relevant given the concentrated weights.
- Synthetic difference-in-differences / matrix completion approaches: Athey et al., Arkhangelsky et al. (Synthetic DiD), and/or Xu’s matrix completion / factor models approach (for comparative checks).
- Conformal inference methods and recent SCM inference advances (Chernozhukov et al. or recent SCM inference literature) — these help provide more formal uncertainty quantification.

Additionally, for DiD/staggered adoption literature (if you include any DiD comparisons), cite Callaway & Sant'Anna (2021) and Goodman-Bacon (2021) / Sun & Abraham (2021) and explain why standard TWFE would be problematic.

Below are specific suggested citations with BibTeX entries you must add to your bibliography and briefly discuss in the paper (why relevant):

- Ben-Michael, Feller, Rothstein (Augmented SCM)
  - Why relevant: Provides bias correction and improves inference when SCM weights are highly concentrated or pre-fit is imperfect.
  - BibTeX:
    @article{benmichael2021augmented,
      author = {Ben-Michael, Eran and Feller, Avi and Rothstein, Jacob},
      title = {The Augmented Synthetic Control Method},
      journal = {Journal of the American Statistical Association},
      year = {2021},
      volume = {116},
      pages = {1789--1803}
    }

- Arkhangelsky et al. (Synthetic Difference-in-Differences) — relevant alternative
  - Why relevant: Combines features of SCM and DiD; useful when panels have staggered shocks or when donor selection is challenging.
  - BibTeX:
    @article{arkhangelsky2021synthetic,
      author = {Arkhangelsky, Dmitry and Athey, Susan and Hirshberg, Daniel and Imbens, Guido and Wager, Stefan},
      title = {Synthetic Difference-in-Differences},
      journal = {American Economic Review},
      year = {2021},
      volume = {111},
      pages = {4088--4118}
    }

- Callaway & Sant'Anna (DiD with multiple time periods/staggered)
  - Why relevant: If authors include any DiD-style comparisons, this shows appropriate corrections for heterogeneous treatment timing; also provides contrast to SCM.
  - BibTeX:
    @article{callaway2021difference,
      author = {Callaway, Brantly and Sant’Anna, Pedro H. C.},
      title = {Difference-in-Differences with Multiple Time Periods},
      journal = {Journal of Econometrics},
      year = {2021},
      volume = {225},
      pages = {200--230}
    }

- Goodman-Bacon (TWFE decomposition)
  - Why relevant: Explains pitfalls of TWFE in staggered settings; while not directly applied here, the paper uses a brief DiD comparison; cite for completeness.
  - BibTeX:
    @article{goodmanbacon2018difference,
      author = {Goodman-Bacon, Andrew},
      title = {Difference-in-Differences with Variation in Treatment Timing},
      journal = {Journal of Econometrics},
      year = {2021},
      volume = {225},
      pages = {254--277}
    }

- Imbens & Lemieux (RDD) — only if you attempt RDD; include as standard econometric reference.
  - BibTeX:
    @article{imbens2008regression,
      author = {Imbens, Guido and Lemieux, Thomas},
      title = {Regression Discontinuity Designs: A Guide to Practice},
      journal = {Journal of Econometrics},
      year = {2008},
      volume = {142},
      pages = {615--635}
    }

- Firpo & Possebom (inference for SCM/placebo issues) or Abadie-Permutation discussion:
  - If these exact references are not used, include the general SCM inference literature and discuss the limitations of placebo-based p-values when donors have poor pre-fit.
  - Example BibTeX (if using Firpo & Possebom, 2019):
    @article{firpo2019synthetic,
      author = {Firpo, Sergio and Possebom, Virgilio},
      title = {Synthetic Controls with Staggered Adoption},
      journal = {arXiv preprint arXiv:1903.07388},
      year = {2019}
    }

- Other applied works on housing and environmental regulations that are directly relevant (to position contribution):
  - Glaeser & Gyourko (already cited but double-check citation is correct year and formatting).
  - Recent papers studying supply constraints and price effects from land-use/environmental regulation in Europe or Netherlands-specific housing literature (e.g., Dutch permit/completion data studies). Cite any micro/regional work on Dutch housing supply constraints (e.g., CPB or national studies) to motivate the need for regional analysis.

Action: Add these citations and at least 3–5 paragraphs that place your approach relative to augmented SCM, synthetic DiD, and the strengths/weaknesses of permutation inference when donors have heterogeneous pre-fit.

5. WRITING QUALITY (critical)
Top journals expect crisp, engaging prose. The manuscript is readable but needs significant polishing and reframing to meet that standard.

a) Prose vs. bullets:
- Major sections (Intro, Results, Discussion) are in paragraphs — good.
- Avoid multi-line bullet lists in places where a narrative explanation would be superior (e.g., the Data section’s variable selection paragraphs can remain lists, but the Empirical Strategy/Robustness/Discussion should be fully narrative).
- In particular, the Abstract and Introduction should present a balanced narrative: hook → contribution → internal validity concerns → main results → caveat. Right now the Abstract emphasizes a 5% effect and then reveals the placebo p-value and COVID confounding; re-order to put the main threat to identification earlier and make the contribution conditional on robustness.

b) Narrative flow:
- The Introduction gives a clear overview but would be improved by:
  - A crisp one-sentence statement of the identification challenge.
  - A paragraph that previews what additional analyses will be done to address COVID confounding and donor sensitivity (e.g., regional analyses, permit/completion checks, augmented SCM).
  - A clear statement of what the reader should take away given the placebo p-value (i.e., "Suggestive but not statistically distinguishable").
- The Discussion should provide a tighter policy take-away: if the nitrogen ruling did raise prices, by what mechanism and how should policy balance biodiversity and housing? Right now discussion is somewhat vague.

c) Sentence quality:
- Prose is competent but often passive and sometimes repetitive. Use more active voice and place key insights at paragraph starts. Avoid phrases such as "This paper finds..." repeated; instead, lead with the insight and follow with evidence.
- Example: In the penultimate paragraph of the Introduction, the authors list four numbered findings. Recast into a coherent narrative with explicit statements about the magnitude of uncertainty.

d) Accessibility:
- Explain key technical parts for non-specialists. Examples:
  - Give intuition for why concentrated weights in SCM are problematic (e.g., describe in one paragraph that reliance on a few countries makes the counterfactual fragile if those countries' post-treatment dynamics are idiosyncratic).
  - Explain the difference between time-series SE and permutation p-value and why the latter is the relevant test for SCM.
- When reporting magnitudes, relate index-point changes to real-economy meaning — e.g., what does a 4.5 index-point increase mean in euros or in terms of a typical house price? This helps non-specialists gauge importance.

e) Figures/Tables quality:
- Ensure each figure and table is fully self-contained. Current captions are informative but tighten them. Include notes for data sources, sample period, and the definition of "gap" where used.
- Consider adding a Figure that shows the placebo distribution (post/pre RMSPE ratios) with Netherlands highlighted.
- Add a table that compares donor country characteristics (GDP per capita, homeownership rate, mortgage market features) to show the plausibility of chosen donors.

6. CONSTRUCTIVE SUGGESTIONS (required analyses and improvements)
The paper shows promise. To make it publishable at a top journal the authors should do the following substantive additions and robustness checks (many are required — I mark those I consider essential):

A. Essential (must-do) analyses and fixes
1. Reframe conclusions in light of placebo p-values:
   - The paper’s main claim must be tempered: given p = 0.69, the paper must not claim a causal effect at conventional levels. Present the 4.52 ATT as an observed divergence that is not statistically significant in placebo inference. This affects Abstract, Introduction, and Conclusion.
2. Improve and present proper SCM inference:
   - Present permutation/placebo tests graphically (distribution of post-treatment ATT or post/pre RMSPE ratios).
   - Exclude donors with poor pre-fit per Abadie’s recommendation in one robustness exercise and show p-values both inclusive and exclusive of poor-fit donors.
   - Report p-values based on RMSPE ratio as well as on absolute post-gap.
3. Implement Augmented SCM (Ben-Michael et al. 2021) and compare ATT to baseline SCM:
   - This is essential given the heavy weight concentration and limited donor overlap. Report whether augmented SCM reduces the estimated ATT or changes sign and report associated placebos.
4. Add regional (within-Netherlands) granular analysis:
   - The national HPI is likely to dilute local treatment. Obtain regional (municipality or province) housing price series if possible and exploit cross-sectional variation in exposure to Natura 2000 sites (distance to nearest site; share of land covered; pre-existing permit intensity).
   - Use a differences-in-differences (or staggered DiD if treatment intensity varies across regions and over time) or synthetic controls at the regional level. This would allow stronger identification because treatment intensity varies across space.
   - If regional data are impossible, at least provide direct evidence on supply: time-series of building permits, housing starts, or completions (national and regional). Show whether permits fell after the ruling and whether the timing matches price divergence.
5. Address COVID confounding explicitly:
   - One approach: include COVID-era country-level controls (e.g., stringency index, unemployment, GDP change) or use a two-step approach that first removes a common pandemic factor estimated from donor countries and then applies SCM on residuals.
   - Alternatively, use an event-window analysis focusing on a narrow window (2019Q2–2019Q4) but note low power. Or show that after controlling for pandemic-related shocks (e.g., mortgage rate changes, fiscal supports), the ATT persists.
6. Donor selection and weight sensitivity:
   - Systematically document how donor inclusion/exclusion affects weights and ATT. Implement a leave-many-out (bootstrap over donor subsets) to show the distribution of ATT when varying donor pools.
   - Show convex-hull diagnostics: is Netherlands inside the convex hull of the donors' pre-treatment trajectories? If not, extrapolation may be biasing results.
7. Mechanism checks:
   - Provide direct supply-side evidence (permits, starts, completions), Q&A with industry associations, or administrative counts of projects halted (if available).
   - If possible, show heterogeneity by region and by property type (apartments vs single-family).
8. Improve reporting of uncertainty:
   - Replace the parametric SE/CI with valid SCM-based inference. If authors still wish to present a time-series SE for descriptive purposes, label it explicitly as descriptive and not inferential.

B. Important but less urgent analyses
1. Compare SCM results to alternative estimators:
   - Synthetic difference-in-differences, matrix completion / factor model (e.g., Xu’s method), and other Bayesian SCM variants. If all agree qualitatively, this increases credibility.
2. Placebo test extensions:
   - Time-placebo tests (pretend treatment earlier) to test for pre-trends and check whether the pre-treatment gap is flat.
   - “In-time” permutation — artificially place treatment in earlier years and test whether similar post-treatment gaps arise.
3. Explore the role of macro fundamentals:
   - Show that donor countries' macro trajectories (mortgage rates, GDP growth, unemployment) do not account for the divergence — or control for them in an augmented SCM.

C. Presentation and narrative improvements
1. Rework Abstract/Intro to be more cautious and to highlight uncertainty up front.
2. Add new figures and tables: (i) placebo distribution plot, (ii) regional SCM (if implemented), (iii) supply-side time series (permits/completions), (iv) donor country comparison table (macro/housing institution differences).
3. Emphasize policy implications but clearly state the large uncertainty and need for regional analyses.

7. OVERALL ASSESSMENT
- Key strengths:
  - Policy-relevant question with a clearly defined shock (May 29, 2019 ruling).
  - Use of the synthetic control framework is appropriate in principle for a single-country shock.
  - Good pre-treatment fit reported, and authors perform several robustness checks (leave-one-out, alternative windows, pre-COVID analyses).
- Critical weaknesses:
  - Inference is inadequately implemented and presented (parametric SEs used incorrectly; placebo p-value low significance).
  - Main effect is heavily confounded by COVID-19; pre-COVID window shows negligible effect.
  - Donor-weight concentration (Portugal/Spain/France) makes the SCM fragile; leave-one-out shows sign change when excluding big donors.
  - No direct evidence of the supply mechanism (permits/completions) at national or regional levels.
  - No regional analysis of heterogeneous exposure; national-level aggregation is likely to mask and confound effects.
  - Missing engagement with key recent methodological literature (Augmented SCM, synthetic DiD, matrix completion) and insufficient diagnostic plots for SCM inference.
- Specific suggestions for improvement (recap):
  - Re-run inference using accepted SCM permutation tests and report the permutation distributions graphically.
  - Implement Augmented SCM and compare to baseline SCM.
  - Obtain regional Dutch price and permit/start/completion data and run regional SCM/DiD to isolate local effects.
  - Control for pandemic-era country-specific dynamics via covariates or factor-model de-trending.
  - Add the cited methodological papers and discuss the advantages/drawbacks of chosen inference.
  - Temper language in abstract and intro to reflect weak placebo evidence.

8. DECISION
Given the substantive methodological and identification issues above, the paper is not acceptable in its current form, but the question and data are promising and the project is salvageable with major work — especially by addressing COVID confounding, donor sensitivity, and providing regional/supply-side evidence and proper inference.

DECISION: MAJOR REVISION

(If you choose to resubmit after the above revisions, in the resubmission cover letter please clearly document how each of the "Essential (must-do)" items above were addressed, and provide new figures/tables for SCM diagnostics and regional analyses. I will re-evaluate with a focus on whether the augmented analyses reduce sensitivity to donor composition and the COVID confound, and whether inference supports any causal attribution.)